Earnings ImpactThe 2025 EBITDA falls significantly from previous expectations due to lower realized pricing and reduced Phase 2 volumes.
Price ExpectationsLowering 2025 price, risk skewed positive With oversupply increasing further in 2025, minimal industry discipline, and inventory levels remaining stagnant, we have lowered our price recovery expectations for 2025.
Sales Volume ExpectationsGiven the minimal capex spent thus far on Phase 2 and guided commissioning initiation in 3Q25, we lower our Phase 2 sales volume expectations, now only expecting $37kt of SC sold in the year vs 137kt spodumene prior.